Pay in 4 interest-free payments of $7.48 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Key findings from the Phase 2 data included: Dose-dependent weight loss : Greater reductions in body weight were observed with higher doses, suggesting a clear pharmacological dose-response relationship
"With 7 additional phase 3 readouts expected in 2026..." -- Kenneth Custer, PhD, EVP Lilly Cardiometabolic Health TRIUMPH-1 -- Obesity -- RESULTS (May 2026) TRIUMPH-1 is the pivotal general-obesity trial that forms the basis of Lilly's weight-management regulatory submission
This significant weight loss occurred gradually over time, with most participants experiencing weight loss within the first few weeks of starting treatment
Side effects depend on the drug class
Weight Loss Tablets: Fact Or Fiction
The table lists extended-interval monthly GLP-1 as an emerging category, citing semaglutide monthly in development and tirzepatide weekly or monthly formulation options
US$ 26.13
US$ 22.98
US$ 23.62
US$ 27.02
US$ 29.13
US$ 22.77
US$ 24.89
US$ 21.74
